Rare disease clinical trial enrollment can be difficult to predict without the right site selection strategy.
Small patient populations, delayed diagnosis, and complex referral pathways mean traditional feasibility methods are often not enough. This guide shows how a patient-centered approach can help sponsors make better site decisions and improve enrollment planning.
Read our guide to explore more about:
- Why rare disease trials need a different feasibility approach
- How data, physician insight, and patient advocacy improve site selection
- What common feasibility gaps can delay enrollment
- How a patient-centered strategy can improve enrollment predictability